BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
TyRx enrolls first patient in CITADEL study for AIGISRx™ anti-bacterial envelope with ICD replacements
News | 03. 24. 2010
TYRX
MONMOUTH JUNCTION, N.J., March 24, 2010--(EON: Enhanced Online News) - TYRX, Inc., a leader in the commercialization of implantable medical devices designed to help reduce infection, announced today that it has begun enrollment in CITADEL, the second of two large scale, prospective, multicenter studies.
